🍽️ sulfasalazine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Anti-inflammatory Effects: Sulfasalazine works by reducing inflammation in the digestive tract. It is believed to exert its therapeutic effects through the combined action of its two components: sulfapyridine and 5-aminosalicylic acid (5-ASA or mesalamine). These components help to suppress inflammation and alleviate symptoms associated with IBD.

  2. Ulcerative Colitis: Sulfasalazine is particularly effective in the treatment of mild to moderate ulcerative colitis, a type of inflammatory bowel disease that affects the colon and rectum. It can help induce and maintain remission, reduce the frequency of flare-ups, and improve symptoms such as abdominal pain, diarrhea, and rectal bleeding.

  3. Crohn's Disease: While sulfasalazine is less commonly used for Crohn's disease compared to ulcerative colitis, it may still be prescribed in certain cases, particularly for mild to moderate disease affecting the colon (colonic Crohn's disease). It may help reduce inflammation and symptoms in some individuals with Crohn's disease.

  4. Rheumatoid Arthritis: Sulfasalazine is also sometimes used to treat rheumatoid arthritis, particularly when other medications have been ineffective or poorly tolerated. It can help reduce joint inflammation and pain associated with rheumatoid arthritis and may slow down disease progression.

  5. Mechanism of Action: The exact mechanism of action of sulfasalazine in treating inflammatory bowel diseases and rheumatoid arthritis is not fully understood. However, its anti-inflammatory properties are believed to result from the inhibition of inflammatory mediators and suppression of the immune response in the affected tissues.

  6. Maintenance Therapy: Sulfasalazine is often used as a maintenance therapy in inflammatory bowel diseases to prevent relapses and maintain remission over the long term. It may be used alone or in combination with other medications, such as corticosteroids, immunomodulators, or biologic agents, depending on the severity and extent of the disease.

  7. Side Effects: Common side effects of sulfasalazine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal discomfort, and loss of appetite. These side effects are usually mild and may improve with continued use. Rare but potentially serious side effects may include allergic reactions, liver toxicity, blood disorders, and hypersensitivity reactions.

  8. Monitoring: Patients taking sulfasalazine may require regular monitoring of blood counts, liver function tests, and kidney function tests to monitor for potential side effects and ensure the medication's safety and effectiveness.

  9. Dosage and Administration: The dosage of sulfasalazine varies depending on the condition being treated, the severity of the disease, and individual patient factors. It is typically taken orally in the form of tablets or capsules and may be administered once or twice daily with food or milk to minimize gastrointestinal side effects.

  10. Contraindications: Sulfasalazine is contraindicated in individuals with a known hypersensitivity to sulfasalazine, sulfonamides, or salicylates. It should be used with caution in patients with preexisting kidney or liver disease, blood disorders, or a history of allergic reactions to sulfa drugs.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of sulfasalazine,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by sulfasalazine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Odoribacter genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Odoribacter splanchnicus species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Coprococcus comes species Decreases 📓 Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
[Ruminococcus] torques species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of sulfasalazine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
Acne 0 0
ADHD 0.5 0.2 1.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.2 -1
Allergic Rhinitis (Hay Fever) 0.3 0.1 2
Allergies 0.4 0 0
Allergy to milk products 0.1 0.3 -2
Alopecia (Hair Loss) 0 0
Alzheimer's disease 0.5 0.9 -0.8
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.4 0.1 3
Ankylosing spondylitis 0.2 0 0
Anorexia Nervosa 0.2 0.1 1
Antiphospholipid syndrome (APS) 0.2 0.3 -0.5
Asthma 0.3 0.1 2
Atherosclerosis 0 0.5 0
Atrial fibrillation 0.4 0.6 -0.5
Autism 0.9 0.9 0
benign prostatic hyperplasia 0 0
Bipolar Disorder 0.6 0.2 2
Brain Trauma 0 0.1 0
Carcinoma 0.9 0.5 0.8
Celiac Disease 0.2 0.8 -3
Cerebral Palsy 0 0.1 0
Chronic Fatigue Syndrome 0.6 1.1 -0.83
Chronic Kidney Disease 0.4 0.1 3
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.1 -0.1
Chronic Urticaria (Hives) 0.1 0.1 0
Coagulation / Micro clot triggering bacteria 0.3 0.1 2
Colorectal Cancer 0.7 0 0
Constipation 0.1 0.1 0
Coronary artery disease 0.1 -0.1
COVID-19 1.4 0.9 0.56
Crohn's Disease 1.2 0.7 0.71
cystic fibrosis 0.1 0.1 0
deep vein thrombosis 0.1 0.1 0
Depression 1.4 1.1 0.27
Dermatomyositis 0 0
Eczema 0 0.1 0
Endometriosis 0.5 0.1 4
Epilepsy 0.2 0.7 -2.5
Fibromyalgia 0.8 0.2 3
Functional constipation / chronic idiopathic constipation 0.6 0.3 1
gallstone disease (gsd) 0.3 0.1 2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 0.1
Generalized anxiety disorder 0.1 0.1 0
Gout 0.1 -0.1
Graves' disease 0.3 0.1 2
Halitosis 0 0
Hashimoto's thyroiditis 0.2 0.3 -0.5
Hidradenitis Suppurativa 0.3 0.3
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0 0
hypercholesterolemia (High Cholesterol) 0.1 0.1
hyperglycemia 0 0.3 0
Hyperlipidemia (High Blood Fats) 0 0
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 0.3 0.7 -1.33
Hypothyroidism 0.2 -0.2
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 0 0
Inflammatory Bowel Disease 0.3 0.4 -0.33
Insomnia 0 0.1 0
Intelligence 0.1 0.1
Intracranial aneurysms 0.2 0.2
Irritable Bowel Syndrome 0.2 0.3 -0.5
Liver Cirrhosis 0.9 0.5 0.8
Long COVID 0.7 0.9 -0.29
Low bone mineral density 0.1 -0.1
Lung Cancer 0 0 0
ME/CFS with IBS 0.3 -0.3
ME/CFS without IBS 0.5 0.2 1.5
Menopause 0 0
Metabolic Syndrome 1.2 1 0.2
Mood Disorders 1.8 1.2 0.5
Multiple Sclerosis 0.9 0.4 1.25
Multiple system atrophy (MSA) 0 0
Neuropathy (all types) 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 0.3 -2
NonCeliac Gluten Sensitivity 0 0
Obesity 1.2 0.6 1
obsessive-compulsive disorder 0.5 0.4 0.25
Osteoarthritis 0.1 0.1
Osteoporosis 0.2 0 0
pancreatic cancer 0.1 0.1
Parkinson's Disease 0.8 0.4 1
Polycystic ovary syndrome 0.3 0.2 0.5
Postural orthostatic tachycardia syndrome 0.1 -0.1
Premenstrual dysphoric disorder 0 0.2 0
primary biliary cholangitis 0 0
Psoriasis 0.3 0.4 -0.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.9 0.5 0.8
Rosacea 0.1 0.1 0
Schizophrenia 0.9 0.2 3.5
scoliosis 0.1 0.3 -2
Sjögren syndrome 0.4 0.3 0.33
Sleep Apnea 0.1 0.3 -2
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1
Stress / posttraumatic stress disorder 0.4 0.4 0
Systemic Lupus Erythematosus 1 0.2 4
Tic Disorder 0.1 0.1 0
Tourette syndrome 0 0
Type 1 Diabetes 0.5 0.1 4
Type 2 Diabetes 1.2 0.6 1
Ulcerative colitis 0.2 0.8 -3
Unhealthy Ageing 0.7 0.3 1.33

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.